NCT07571629

Brief Summary

This was a 56-day, single-center, open-label, single-arm exploratory study evaluating within-participant changes in skin-aging parameters after daily oral intake of NatureU® Mind Care BeautyU Caps in adult women. Participants took one capsule daily for 56 days. The primary outcome was change from baseline in crow's-feet wrinkle count at Day 56 assessed by PRIMOS CR imaging. The secondary outcome was change from baseline in stratum corneum hydration at Day 56 assessed by Corneometer CM 825. Additional exploratory outcomes included other wrinkle topography parameters, skin elasticity, radiance, pigmentation, pore-related parameters, dermal thickness and density, and participant-reported skin appearance outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 11, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 8, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 8, 2025

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

April 30, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 6, 2026

Completed
Last Updated

May 6, 2026

Status Verified

April 1, 2026

Enrollment Period

2 months

First QC Date

April 30, 2026

Last Update Submit

April 30, 2026

Conditions

Keywords

NatureUoral beauty supplementskin hydrationPQQ; quercetin; ergothioneine; proanthocyanidins.

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline in Crow's-Feet Wrinkle Count at Day 56

    Crow's-feet wrinkle count was assessed using PRIMOS CR imaging. The primary endpoint was the within-participant change from baseline to Day 56.

    Baseline and Day 56

Secondary Outcomes (1)

  • Change From Baseline in Stratum Corneum Hydration at Day 56

    Baseline and Day 56

Other Outcomes (1)

  • Change From Baseline in Additional Wrinkle Topography Parameters at Day 28 and Day 56

    Day 28, Day 56

Study Arms (1)

NatureU® Mind Care BeautyU Caps

EXPERIMENTAL

Participants received NatureU® Mind Care BeautyU Caps, one capsule orally once daily for 56 days.

Dietary Supplement: NatureU® Mind Care BeautyU Caps

Interventions

An oral nutricosmetic supplement containing PQQ, quercetin, ergothioneine, cranberry polyphenols, and related formulation components. Participants took one capsule daily for 56 days.

NatureU® Mind Care BeautyU Caps

Eligibility Criteria

Age36 Years - 56 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Adult women meeting the age range specified in the study protocol.
  • Participants with visible skin-aging concerns such as crow's-feet wrinkles, dryness, or reduced skin hydration.
  • Participants willing to take the study product once daily for 56 days.
  • Participants willing to complete scheduled skin assessments at baseline, Day 28, and Day 56.
  • Participants who provided written informed consent.

You may not qualify if:

  • Known allergy or intolerance to any ingredient of the study product.
  • Use of other oral or topical products that could interfere with skin-aging assessments during the study period.
  • Recent cosmetic dermatology procedures or treatments that could affect the target assessment areas.
  • Pregnancy, lactation, or planned pregnancy during the study period.
  • Any condition judged by the investigator to make participation inappropriate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CTI AiPu Medical Laboratory (Shanghai) Co., Ltd

Shanghai, Shanghai Municipality, 200040, China

Location

Study Officials

  • Luke Law, Dr

    OmniSolutions Laboratory Holdings Limited

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 30, 2026

First Posted

May 6, 2026

Study Start

January 11, 2025

Primary Completion

March 8, 2025

Study Completion

March 8, 2025

Last Updated

May 6, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared due to privacy protection and ethical considerations.

Available IPD Datasets

Clinical Study Report Access

Locations